Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Melanoma 11Uveal Melanoma 3Skin Neoplasms 2Neoplasms 2Neoplasm Metastasis 2Glioblastoma 2Carcinoma, Renal Cell 2Urologic Neoplasms 1Prostatic Neoplasms 1Neoplasms by Site 1Myelodysplastic Syndromes 1Lung Neoplasms 1Leukemia, Myeloid, Acute 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Lymphocytic, Chronic, B-Cell 1Gliosarcoma 1Eye Neoplasms 1Breast Neoplasms 1Adenoma, Islet Cell 1

Interventions

Imatinib Mesylate 60Cyclophosphamide 57fludarabine phosphate 51fludarabine 43Whole-Body Irradiation 41Mycophenolic Acid 41Tacrolimus 33nilotinib 31Dasatinib 31Busulfan 29Peripheral Blood Stem Cell Transplantation 23Cyclosporine 22Melphalan 21Thiotepa 20Granulocyte Colony-Stimulating Factor 19Filgrastim 18thymoglobulin 17Cytarabine 17Antilymphocyte Serum 15Stem Cell Transplantation 14sargramostim 13Methotrexate 13ponatinib 12asciminib 10Cyclosporins 10Cord Blood Stem Cell Transplantation 10bosutinib 9Rituximab 9Interferon-alpha 9Clofarabine 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Leukemia, Myelogenous, Chronic, BCR-ABL Positive × montanide ISA 51 × Clear all
NCT00488592 2021-07-12

Peptide Vaccinations to Treat Patients With Low-Risk Myeloid Cancers

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
10 enrolled 7 charts
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡